Zacks Research Downgrades Aprea Therapeutics (NASDAQ:APRE) to Strong Sell

Aprea Therapeutics (NASDAQ:APRE) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

APRE has been the topic of several other research reports. HC Wainwright dropped their price objective on Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $8.00.

Aprea Therapeutics Stock Down 0.3%

Aprea Therapeutics stock opened at $0.90 on Tuesday. The stock has a market cap of $6.29 million, a P/E ratio of -0.42 and a beta of 1.44. The company’s 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.40. Aprea Therapeutics has a 52 week low of $0.84 and a 52 week high of $4.65.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). The business had revenue of $0.00 million during the quarter. Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%. On average, equities analysts anticipate that Aprea Therapeutics will post -2.55 EPS for the current year.

Insider Transactions at Aprea Therapeutics

In other news, Director Marc Duey bought 21,459 shares of the company’s stock in a transaction dated Wednesday, December 10th. The stock was bought at an average cost of $1.17 per share, for a total transaction of $25,107.03. Following the completion of the acquisition, the director owned 256,155 shares in the company, valued at approximately $299,701.35. This trade represents a 9.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 13.63% of the stock is currently owned by company insiders.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.